tenm4 Antibody

What is TENM4 and what are its primary biological functions?

TENM4 (Teneurin transmembrane protein 4) is a large transmembrane protein belonging to the teneurin protein family with a molecular weight of approximately 308 kDa and consisting of 2769 amino acid residues in humans . It exhibits subcellular localization in the cell membrane, nucleus, and cytoplasm, with notable expression in the cerebral cortex . TENM4 plays significant roles in neural development, particularly in regulating proper connectivity establishment within the nervous system . The protein is involved in neuronal plasticity and signaling pathways, contributing to neurogenesis, neurite outgrowth, and neuronal differentiation . Recent research has also implicated TENM4 in various pathological conditions, including mental disorders such as schizophrenia, bipolar disorder, and autism, as well as in several types of cancer, particularly breast cancer . In cancer biology, TENM4 appears to influence cellular processes such as migration, self-renewal, and stemness, suggesting its potential involvement in tumor progression and metastasis .

How is TENM4 expression regulated in normal and disease states?

In breast cancer, TENM4 expression is significantly upregulated, particularly in cancer stem cells (CSCs) compared to epithelial cancer cells. RNA sequencing data revealed a greater than 7-fold increase in 4T1 murine TNBC cells and more than 5-fold increase in HCC1806 human TNBC cells growing as tumorspheres compared to their epithelial counterparts . This upregulation has been validated at both mRNA and protein levels in multiple TNBC cell lines . Interestingly, queries of TCGA database through Oncomine have shown higher TENM4 mRNA levels in both ductal and lobular invasive carcinoma of the breast compared to normal breast tissue . The regulatory mechanisms controlling these expression changes remain an active area of investigation.

What are the most effective applications for TENM4 antibodies in cancer research?

TENM4 antibodies have proven particularly valuable for investigating TENM4's role in cancer biology through several methodological approaches:

• Expression Analysis: Anti-TENM4 antibodies are effectively used in Western blotting, immunohistochemistry, and flow cytometry to quantify and localize TENM4 expression in tumor samples and cell lines . These techniques have revealed critical upregulation patterns in cancer stem cells compared to bulk tumor cells.

• Functional Studies: Antibodies targeting TENM4 can be utilized to neutralize its function, allowing researchers to investigate its role in cellular processes such as migration, invasion, and tumorsphere formation . This approach has demonstrated TENM4's contribution to cancer cell aggressiveness.

• Signaling Pathway Analysis: TENM4 antibodies have helped elucidate downstream signaling mechanisms, including the finding that TENM4 silencing impairs Focal Adhesion Kinase (FAK) phosphorylation , suggesting its involvement in cell adhesion and migration pathways.

• Biomarker Development: Detection of TENM4 in plasma samples using antibody-based methods has shown promise for identifying TNBC patients and monitoring disease progression .

For optimal results, researchers should select antibodies validated specifically for their intended application, as performance can vary significantly between techniques such as ELISA, flow cytometry, or immunohistochemistry .

How should researchers validate TENM4 antibody specificity for experimental procedures?

Validating TENM4 antibody specificity is crucial for obtaining reliable experimental results. Researchers should implement a multi-faceted validation approach:

• Multiple Antibody Comparison: Utilize antibodies from different sources or those targeting different epitopes. Commercial vendors offer various anti-human TENM4 recombinant antibodies with different clonal origins (e.g., clones 1.48, 1.58, 2.36) that can be compared for consistent detection patterns.

• Positive and Negative Controls: Include cell lines or tissues known to express high levels of TENM4 (e.g., TNBC tumorspheres, neural tissues) alongside those with minimal expression . Ideally, TENM4 knockout or knockdown samples should be used as negative controls.

• Western Blot Analysis: Confirm single-band detection at the expected molecular weight (~308 kDa), though post-translational modifications like glycosylation may affect the observed size .

• Peptide Competition Assay: Pre-incubation with the immunizing peptide should abolish specific staining.

• Correlation with mRNA Expression: Compare protein detection with RT-PCR results across multiple samples to ensure concordance between transcript and protein levels, as demonstrated in studies with breast cancer cell lines .

These validation steps help ensure experimental observations accurately reflect TENM4 biology rather than non-specific antibody interactions.

How does TENM4 contribute to schizophrenia pathophysiology?

TENM4 has emerged as a significant genetic risk factor in schizophrenia (SCZ) through several pathophysiological mechanisms:

• Genetic Mutations: Target sequencing of TENM4 in 68 SCZ families has identified pathogenic mutations that may contribute to disease susceptibility . These mutations appear to affect TENM4's functional domains critical for neural development and signaling.

• Neural Circuit Disruption: Aberrant expression of Ten-m (the TENM4 ortholog in animal models) leads to impaired neural circuits that manifest as behavioral abnormalities including lower learning ability, sleep reduction, and increased aggressiveness . These behavioral changes parallel some clinical manifestations observed in schizophrenia patients.

• Molecular Pathway Alterations: RNA sequencing analysis revealed that disrupted Ten-m expression affects biological processes related to stimulus perception and metabolism . Gene Ontology enrichment analysis specifically highlighted effects on neurogenesis and ATPase activity, suggesting TENM4 mutations may impair neural development and energy metabolism in the brain .

• Synaptic Function: TENM4's role in neuronal plasticity suggests that its dysfunction could impair synaptic formation and maintenance, contributing to the aberrant connectivity hypothesized to underlie schizophrenia .

This multifaceted impact on neural development and function positions TENM4 as an important contributor to the neurodevelopmental aspects of schizophrenia pathophysiology.

What is the current understanding of TENM4's role in breast cancer progression?

TENM4 has been implicated in breast cancer progression through several mechanisms that influence tumor cell behavior and patient outcomes:

These findings collectively position TENM4 as a promising target for therapeutic intervention in breast cancer, particularly for aggressive subtypes like TNBC where effective targeted therapies remain limited.

What are the optimal methods for detecting TENM4 expression in clinical samples?

Detection of TENM4 in clinical samples requires careful consideration of technical approaches based on the specific research questions:

• Tissue-Based Detection:

  • Immunohistochemistry (IHC): Provides spatial information about TENM4 expression in tumor tissues. Requires optimization of fixation protocols, antigen retrieval methods, and antibody dilutions for the large transmembrane protein .

  • RNA in situ hybridization (RNA-ISH): Can complement IHC by detecting TENM4 mRNA with potentially higher specificity when antibody performance is suboptimal.

• Liquid Biopsy Approaches:

  • ELISA: Several anti-TENM4 antibodies have been specifically validated for ELISA applications, making this a reliable method for detecting soluble or shed TENM4 in patient plasma or serum .

  • Flow cytometry: Useful for detecting membrane-bound TENM4 in circulating tumor cells, with commercial antibodies specifically validated for this application .

• Molecular Detection:

  • RT-PCR: Semi-quantitative or quantitative RT-PCR has been successfully employed to measure TENM4 mRNA levels in cancer cell lines and patient samples .

  • RNA sequencing: Provides comprehensive expression data and has revealed significant upregulation of TENM4 in CSC-enriched populations .

For clinical samples, a multi-modal approach combining protein and mRNA detection methods is recommended to overcome limitations of individual techniques. Research has shown that TENM4 can be reliably detected in plasma from tumor-bearing patients, suggesting liquid biopsy approaches may be particularly valuable for monitoring purposes .

How can researchers effectively silence or modulate TENM4 expression in experimental models?

Researchers have several methodological options for manipulating TENM4 expression to study its function:

• RNA Interference (RNAi):

  • siRNA transfection: Effective for transient TENM4 knockdown in cell lines, with published studies demonstrating successful silencing that resulted in impaired tumorsphere formation and migratory capacity .

  • shRNA stable expression: Provides longer-term silencing for in vivo studies and has been used to demonstrate TENM4's role in tumor progression.

• CRISPR-Cas9 Gene Editing:

  • Knockout generation: Complete elimination of TENM4 expression can reveal its necessity for cancer cell functions.

  • Knock-in approaches: Introduction of specific mutations identified in patient samples can help investigate their functional consequences.

• Antibody-Based Functional Blocking:

  • Neutralizing anti-TENM4 antibodies have been developed that can inhibit the metastasis of tumors, providing a pharmacological approach to TENM4 inhibition .

• miRNA-Mediated Regulation:

  • miR-708, which is spliced from TENM4 mRNA, has tumorigenic roles when deregulated and represents a unique regulatory mechanism that can be experimentally manipulated .

When designing TENM4 modulation experiments, researchers should consider potential compensatory mechanisms involving other teneurin family members (TENM1-3), and include comprehensive controls to validate knockdown efficiency at both mRNA and protein levels.

How should researchers reconcile contradictory findings about TENM4's role as oncogene or tumor suppressor?

The apparently contradictory roles of TENM4 as either an oncogene or tumor suppressor present a significant challenge for researchers. To reconcile these contradictions, consider these methodological approaches:

• Context-Dependent Analysis: TENM4 exhibits tissue-specific effects, functioning differently across cancer types. In silico analysis has shown increased TENM4 expression in lung adenocarcinoma, lower grade glioma, and pancreatic adenocarcinoma compared to normal tissues, while decreased expression is observed in skin cutaneous melanoma, ovarian serous cystadenocarcinoma, and testicular germ cell tumors . This suggests that thorough characterization of TENM4's function should be performed in the specific tissue context under investigation.

• Molecular Subtype Stratification: Even within the same cancer type, TENM4 may have different roles depending on molecular subtypes. For instance, while TENM4 overexpression generally correlates with worse prognosis in breast cancer, the magnitude of effect varies across subtypes (TNBC, HER2-positive, PR-positive, and ER-positive) .

• Protein Domain-Specific Functions: As a large protein with multiple domains, different regions of TENM4 may mediate distinct and sometimes opposing functions. Researchers should consider generating domain-specific constructs or antibodies to dissect these potentially divergent functions.

• Interaction Partner Analysis: TENM4's role may be determined by its protein interaction network, which could vary between tissues. Techniques such as co-immunoprecipitation followed by mass spectrometry can identify tissue-specific binding partners that might explain contextual differences.

• Epigenetic Regulation Assessment: Differences in TENM4's impact might reflect varied epigenetic regulation patterns across tissues, potentially leading to expression of different isoforms with distinct functions.

By systematically addressing these factors, researchers can develop a more nuanced understanding of TENM4's context-dependent roles in cancer biology.

What is the relationship between TENM4 and miR-708 in cancer biology?

The relationship between TENM4 and miR-708 represents an intriguing regulatory mechanism in cancer biology:

This complex relationship highlights the need for integrated approaches examining both TENM4 and miR-708 simultaneously in cancer research.

What controls should be included when using TENM4 antibodies for cancer stem cell identification?

When using TENM4 antibodies to identify and characterize cancer stem cells (CSCs), researchers should implement comprehensive control strategies:

• Validation Controls:

  • Isotype Controls: Include appropriate isotype-matched control antibodies to establish baseline non-specific binding, particularly important for flow cytometry applications .

  • Absorption Controls: Pre-incubate anti-TENM4 antibodies with recombinant TENM4 protein to confirm binding specificity.

  • TENM4-knockdown Samples: Use siRNA or shRNA-mediated TENM4 silencing to generate negative control samples with reduced TENM4 expression .

• Functional Validation:

  • CSC Marker Co-expression: Validate TENM4+ populations through co-expression analysis with established CSC markers (e.g., ALDH activity, which has been used to confirm CSC properties in MDA-MB-231 tumorspheres) .

  • Self-renewal Assays: Confirm stemness properties of TENM4+ cells through serial tumorsphere formation assays or limiting dilution assays.

  • In vivo Tumorigenicity: Assess tumor-initiating capacity of TENM4+ versus TENM4- cells through limiting dilution transplantation studies.

• Technical Controls:

  • Multiple Antibody Clones: Verify findings using different anti-TENM4 antibody clones (e.g., clones 1.48, 1.58, 2.36) to ensure results are not antibody-specific artifacts.

  • Multiple Detection Methods: Combine antibody-based detection with mRNA analysis to confirm TENM4 expression at both protein and transcript levels .

• Comparative Controls:

  • Normal Tissue Stem Cells: Compare TENM4 expression in CSCs with normal tissue stem cells to identify cancer-specific patterns.

  • Cross-cancer Comparison: Assess TENM4 expression in CSCs from different cancer types to determine if it represents a universal or cancer-specific CSC marker.

Implementation of these controls ensures robust and reproducible identification of TENM4-expressing cancer stem cells.

How can researchers best assess the functional significance of TENM4 mutations identified in patient samples?

Evaluating the functional impact of TENM4 mutations identified in patient samples requires a systematic multi-level approach:

• In Silico Analysis:

  • Structural Prediction: Use protein modeling tools to predict how mutations might affect TENM4's three-dimensional structure, particularly within functional domains.

  • Conservation Analysis: Assess evolutionary conservation of mutated residues across species to infer functional importance.

  • Pathway Impact Prediction: Employ algorithms to predict effects on protein-protein interactions, signaling pathways, or subcellular localization.

• Cellular Models:

  • CRISPR-Cas9 Knock-in: Generate isogenic cell lines harboring specific patient-derived mutations to directly compare with wild-type cells.

  • Overexpression Studies: Compare wild-type versus mutant TENM4 overexpression effects on cellular phenotypes relevant to disease (e.g., in schizophrenia studies, assess neuronal morphology, connectivity, and synaptic function) .

  • Signaling Pathway Analysis: Investigate how mutations affect downstream signaling, particularly FAK phosphorylation which has been linked to TENM4 function in cancer cells .

• Functional Assays:

  • For Cancer-Related Mutations: Assess effects on cell proliferation, migration (demonstrated to be affected by TENM4 silencing) , invasion, stemness (tumorsphere formation), and drug resistance.

  • For Neuropsychiatric Mutations: Evaluate neuronal differentiation, neurite outgrowth, synapse formation, and electrophysiological properties .

• Animal Models:

  • Conditional Knock-in Models: Generate animals expressing patient-specific mutations in relevant tissues to assess physiological and behavioral consequences.

  • Patient-Derived Xenografts: For cancer mutations, establish PDX models from mutation-carrying tumors to evaluate growth patterns and therapeutic responses.

• Multi-omics Integration:

  • Transcriptomics: Compare gene expression profiles between wild-type and mutant TENM4-expressing systems to identify dysregulated pathways.

  • Proteomics: Identify altered protein interaction networks resulting from TENM4 mutations.

This comprehensive approach enables researchers to establish causative relationships between TENM4 mutations and observed disease phenotypes, potentially revealing new therapeutic targets.

What is the potential of TENM4 as a therapeutic target in triple-negative breast cancer?

TENM4 demonstrates considerable promise as a therapeutic target in triple-negative breast cancer (TNBC) based on several lines of evidence:

The cell surface location of TENM4, its enrichment in cancer stem cells, and its correlation with poor prognosis collectively position it as a promising target for developing novel therapeutics for TNBC, a subtype with limited targeted treatment options.

How might TENM4 antibodies be optimized for diagnostic applications in cancer detection?

Optimizing TENM4 antibodies for cancer diagnostic applications requires addressing several technical and biological considerations:

• Epitope Selection and Antibody Engineering:

  • Cancer-Specific Epitopes: Identify regions of TENM4 that may be uniquely accessible or modified in cancer cells compared to normal tissues.

  • Affinity Optimization: Engineer antibodies with optimized binding kinetics (high affinity but appropriate off-rates) for diagnostic applications.

  • Format Diversification: Develop various antibody formats (full IgG, Fab fragments, single-chain antibodies) optimized for different diagnostic platforms .

• Platform-Specific Optimization:

  • Immunohistochemistry: Optimize fixation compatibility, antigen retrieval methods, and signal amplification systems for tissue-based diagnostics.

  • Liquid Biopsy Applications: Develop highly sensitive ELISA or other immunoassay formats capable of detecting low levels of circulating TENM4 in patient blood samples .

  • Flow Cytometry: Optimize fluorophore conjugation and staining protocols for detecting TENM4-positive circulating tumor cells .

• Validation Strategies:

  • Multi-cohort Validation: Test antibody performance across diverse patient populations and sample types.

  • Correlative Studies: Validate diagnostic utility by correlating TENM4 detection with established clinical parameters and outcomes.

  • Reproducibility Assessment: Conduct inter-laboratory comparisons to ensure consistent performance across testing sites.

• Clinical Application Refinement:

  • Cancer Subtype Specificity: Determine if antibodies can distinguish TENM4 expression patterns specific to particular cancer subtypes (e.g., TNBC vs. other breast cancers) .

  • Prognostic vs. Predictive Applications: Establish whether TENM4 detection better serves as a general prognostic marker or as a predictive biomarker for specific therapeutic approaches.

  • Combination Biomarker Panels: Integrate TENM4 detection with other biomarkers to improve sensitivity and specificity.

By addressing these considerations, researchers can develop TENM4 antibody-based diagnostic tools that may help identify patients with more aggressive disease who could benefit from intensified monitoring or novel therapeutic approaches targeting TENM4.

What experimental approaches could reveal new insights into TENM4's structure-function relationships?

Elucidating TENM4's structure-function relationships requires innovative experimental approaches spanning multiple scales:

• Structural Biology Techniques:

  • Cryo-Electron Microscopy: Determine high-resolution structures of full-length TENM4 or its functional domains to understand conformational states.

  • X-ray Crystallography: Resolve atomic-level structures of TENM4 domains, particularly those implicated in protein-protein interactions.

  • NMR Spectroscopy: Characterize dynamic regions and binding interfaces, especially for smaller functional domains.

  • Molecular Dynamics Simulations: Model conformational changes and predict effects of disease-associated mutations.

• Domain-Specific Functional Analysis:

  • Domain Deletion/Mutation Studies: Generate constructs with specific domains deleted or mutated to map their contributions to TENM4 functions in migration, stemness, and signaling .

  • Chimeric Protein Analysis: Create fusion proteins swapping domains between TENM4 and other teneurin family members to identify unique functional elements.

  • Post-translational Modification Mapping: Characterize glycosylation and other modifications across TENM4's structure and determine their functional significance .

• Protein Interaction Networks:

  • Proximity Labeling: Use BioID or APEX approaches to identify proteins that interact with specific TENM4 domains in living cells.

  • Crosslinking Mass Spectrometry: Map interaction interfaces at high resolution.

  • Yeast Two-Hybrid Screening: Identify specific binding partners for individual TENM4 domains.

• Advanced Cellular Imaging:

  • Super-Resolution Microscopy: Visualize TENM4 distribution and clustering at the nanoscale.

  • Live-Cell FRET Analysis: Monitor dynamic interactions between TENM4 and signaling partners such as FAK .

  • Correlative Light and Electron Microscopy: Connect TENM4 localization to ultrastructural features.

• In Vivo Structure-Function Studies:

  • Domain-Specific Knock-in Models: Generate animals expressing TENM4 with specific domain modifications to assess physiological consequences.

  • Tissue-Specific Expression Systems: Investigate domain requirements in relevant tissues (neural tissue for schizophrenia studies, mammary tissue for breast cancer models) .

These approaches would provide a comprehensive understanding of how TENM4's complex structure relates to its diverse functions in development and disease, potentially revealing new intervention points for therapeutic development.

What emerging technologies could advance TENM4 research in neuropsychiatric and cancer fields?

Several cutting-edge technologies show promise for accelerating TENM4 research across both neuropsychiatric and cancer fields:

• Single-Cell Multi-Omics:

  • Single-Cell RNA/Protein Co-Detection: Simultaneously measure TENM4 transcript and protein levels in individual cells to understand expression heterogeneity.

  • Spatial Transcriptomics: Map TENM4 expression within tissue architecture to identify microenvironmental influences.

  • Single-Cell ATAC-Seq: Characterize chromatin accessibility at the TENM4 locus to understand its epigenetic regulation.

• Advanced Genome Editing:

  • Base and Prime Editing: Introduce precise patient-derived mutations with minimal off-target effects.

  • CRISPR Activation/Interference: Modulate TENM4 expression in specific cell populations without genetic modification.

  • In Vivo CRISPR Screening: Identify genetic modifiers of TENM4 function in relevant disease models.

• 3D Cellular Models:

  • Brain Organoids: Study TENM4's role in neuropsychiatric disorders using patient-derived 3D neural cultures .

  • Tumor Organoids: Investigate TENM4 in cancer progression using patient-derived 3D tumor models that better recapitulate in vivo architecture .

  • Organ-on-Chip Technology: Examine TENM4's function in dynamic microenvironments with controlled physical and chemical parameters.

• Advanced Imaging Technologies:

  • Light Sheet Microscopy: Visualize TENM4 distribution in whole tissues with minimal phototoxicity.

  • Expansion Microscopy: Physically enlarge samples to achieve super-resolution imaging of TENM4 and interacting partners.

  • Intravital Imaging: Monitor TENM4-expressing cells in living organisms during disease progression.

• Artificial Intelligence Applications:

  • Deep Learning for Image Analysis: Automatically identify patterns in TENM4 distribution across large tissue datasets.

  • Network Analysis Algorithms: Integrate multi-omics data to predict TENM4's position in disease-specific regulatory networks.

  • Drug Discovery AI: Design small molecules or peptides targeting specific TENM4 domains.

• Novel Therapeutic Approaches:

  • Antibody-Drug Conjugates: Target TENM4-expressing cancer cells with antibody-linked cytotoxic agents .

  • RNA Therapeutics: Develop splice-modulating oligonucleotides that could alter TENM4/miR-708 balance .

  • Proteolysis-Targeting Chimeras (PROTACs): Design bifunctional molecules that selectively degrade TENM4 protein.